To solve the critical challenge of hiring expensive, specialized talent, Curie.Bio offers its portfolio companies access to a 100+ person team of elite "drug makers" on a fractional, at-cost basis. This provides world-class expertise on demand without the burden of full-time payroll, de-risking early development.

When an experienced founder starts a new venture based on their own vision, the equity split doesn't need to be 50/50. By framing it as 'my deal,' the primary founder can retain a supermajority (e.g., 80%) while giving a technical co-founder a smaller but still meaningful stake.

Beyond accelerators, pure investors, and traditional company builders, this new VC model provides "hardcore primary data generation drug making support." It involves a team of 10+ experts engaging with a startup multiple times per day, offering an intensity of operational involvement that other models lack.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

By defining the entrepreneur as the primary customer, a VC firm changes its entire operating model. This customer-centric view informs decisions on partner incentives (removing attribution), community building, and support services. The result is a powerful brand that attracts the best founders and generates high-fidelity deal flow through referrals.

A 50/50 equity split should not be the default. The conversation must focus on what unique, "unfair advantages" each founder brings to the table. This could be a significant pre-built audience, a deep professional network, or personal capital. The idea itself is rarely worth any equity.

Large, contrarian investments feel like career risk to partners in a traditional VC firm, leading to bureaucracy and diluted conviction. Founder-led firms with small, centralized decision-making teams can operate with more decisiveness, enabling them to make the bold, potentially firm-defining bets that consensus-driven partnerships would avoid.

In early-stage investing, the quality of the founder can be more important than the initial business concept. A strong founder is seen as someone who will eventually find success, even if the first idea requires a pivot.

Startups need elite talent to succeed but can't afford or attract it. Curie.bio solves this by providing its portfolio companies with on-demand, fractional access to a team of over 100 world-class drug hunters. This allows founders to tap into top-tier expertise without incurring high fixed costs.